Lanadelumab Completed Phase 3 Trials for Hereditary Angioedema (HAE) / Coronavirus Disease 2019 (COVID‑19) Prevention

IndicationsStatusPurposePhase
CompletedPrevention3
clinicaltrials.gov IdentifierTitleDrugs
NCT04070326A Study of Lanadelumab to Prevent Hereditary Angioedema (HAE) Attacks in Children